Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV: TKUN)
Israel
· Delayed Price · Currency is ILS · Price in ILA
36.20
-1.80 (-4.74%)
Dec 22, 2024, 3:50 PM IDT
TLV: TKUN Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 42.55 | 44.23 | 49.3 | 37.03 | 21.66 | - | Upgrade
|
Revenue | 42.55 | 44.23 | 49.3 | 37.03 | 21.66 | - | Upgrade
|
Revenue Growth (YoY) | -16.05% | -10.28% | 33.13% | 70.97% | - | - | Upgrade
|
Cost of Revenue | 38.87 | 32.7 | 31.19 | 29.38 | 7.37 | - | Upgrade
|
Gross Profit | 3.67 | 11.53 | 18.11 | 7.65 | 14.29 | - | Upgrade
|
Selling, General & Admin | 18.76 | 22.82 | 23.95 | 27.66 | 28.86 | 9.31 | Upgrade
|
Research & Development | 1.49 | 3.89 | 5.16 | 7.2 | 2.16 | 0.63 | Upgrade
|
Other Operating Expenses | 24.71 | 64.76 | -0.33 | 0.85 | 5.07 | - | Upgrade
|
Operating Expenses | 54.55 | 104.76 | 44.45 | 50.7 | 46.48 | 9.95 | Upgrade
|
Operating Income | -50.88 | -93.23 | -26.34 | -43.05 | -32.2 | -9.95 | Upgrade
|
Interest Expense | -2.07 | -2.3 | -1.77 | -1.28 | -1.19 | -0.28 | Upgrade
|
Interest & Investment Income | - | - | 0.09 | 0.01 | 0.05 | - | Upgrade
|
Earnings From Equity Investments | - | -0.38 | - | - | - | - | Upgrade
|
Other Non Operating Income (Expenses) | - | - | - | - | - | -0.7 | Upgrade
|
EBT Excluding Unusual Items | -52.95 | -95.91 | -28.02 | -44.32 | -33.33 | -10.93 | Upgrade
|
Impairment of Goodwill | -1.34 | -1.34 | -17.57 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | -0.3 | -0.3 | 1.93 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | - | - | -0.13 | - | Upgrade
|
Asset Writedown | - | - | -15.27 | - | - | - | Upgrade
|
Legal Settlements | - | - | - | - | -1.35 | - | Upgrade
|
Other Unusual Items | 3.56 | 3.56 | 9.79 | 10.29 | -0.21 | - | Upgrade
|
Pretax Income | -51.04 | -93.99 | -49.14 | -34.03 | -35.02 | -10.93 | Upgrade
|
Income Tax Expense | 0.03 | 0.03 | 0.01 | - | -0.27 | - | Upgrade
|
Earnings From Continuing Operations | -51.06 | -94.02 | -49.15 | -34.03 | -34.75 | -10.93 | Upgrade
|
Minority Interest in Earnings | 1.01 | 5.13 | 0.91 | 1.38 | 1.81 | 0.04 | Upgrade
|
Net Income | -50.05 | -88.89 | -48.24 | -32.65 | -32.94 | -10.89 | Upgrade
|
Net Income to Common | -50.05 | -88.89 | -48.24 | -32.65 | -32.94 | -10.89 | Upgrade
|
Shares Outstanding (Basic) | 57 | 63 | 49 | 42 | 34 | 18 | Upgrade
|
Shares Outstanding (Diluted) | 57 | 63 | 49 | 42 | 34 | 18 | Upgrade
|
Shares Change (YoY) | 1.37% | 29.54% | 15.79% | 23.01% | 86.23% | 160.53% | Upgrade
|
EPS (Basic) | -0.87 | -1.41 | -0.99 | -0.78 | -0.96 | -0.59 | Upgrade
|
EPS (Diluted) | -0.87 | -1.41 | -0.99 | -0.78 | -0.96 | -0.59 | Upgrade
|
Free Cash Flow | 4.21 | -4.12 | -23.2 | -33.49 | -50.69 | -16.31 | Upgrade
|
Free Cash Flow Per Share | 0.07 | -0.07 | -0.48 | -0.80 | -1.48 | -0.89 | Upgrade
|
Gross Margin | 8.63% | 26.06% | 36.73% | 20.66% | 65.96% | - | Upgrade
|
Operating Margin | -119.59% | -210.79% | -53.44% | -116.25% | -148.64% | - | Upgrade
|
Profit Margin | -117.64% | -200.97% | -97.85% | -88.17% | -152.09% | - | Upgrade
|
Free Cash Flow Margin | 9.90% | -9.31% | -47.07% | -90.43% | -234.06% | - | Upgrade
|
EBITDA | -21.6 | -37.83 | -8.37 | -25.89 | -19.89 | -9.94 | Upgrade
|
EBITDA Margin | -50.78% | -85.54% | -16.97% | -69.92% | -91.84% | - | Upgrade
|
D&A For EBITDA | 29.28 | 55.39 | 17.98 | 17.15 | 12.3 | 0.01 | Upgrade
|
EBIT | -50.88 | -93.23 | -26.34 | -43.05 | -32.2 | -9.95 | Upgrade
|
EBIT Margin | -119.59% | -210.79% | -53.44% | -116.25% | -148.64% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.